Innovation - 12:01
Swiss- Austrian high- level meeting to share information and perspectives on higher education, research and innovation
Swiss- Austrian high- level meeting to share information and perspectives on higher education, research and innovation
Pharmacology - 07:01
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
wire - news in brief
Life Sciences - Sep 23
Environment - Sep 23
A pioneering study carried out at EPFL shows that the amount of daylight in a room can influence our thermal comfort and how well we tolerate heat or cold.
Life Sciences - Sep 20
UNIGE researchers have demonstrated how the harsh sounds used in alarm systems hold the brain's attention by stimulating its aversion networks.
Category
Results 1 - 50 of 346.
History of technology: accolades to USI researcher Maria Rikitianskaia
The International Committee for the History of Technology (ICOHTEC) honoured Maria Rikitianskaia for her doctoral work which was unanimously voted as the best book on the history of technology, published in 2019 by young researchers. The researcher of USI Institute of Media and Journalism won the Turriano ICOHTEC Prize , dedicated to the best book on the history of technology written by a young researcher.
The International Committee for the History of Technology (ICOHTEC) honoured Maria Rikitianskaia for her doctoral work which was unanimously voted as the best book on the history of technology, published in 2019 by young researchers. The researcher of USI Institute of Media and Journalism won the Turriano ICOHTEC Prize , dedicated to the best book on the history of technology written by a young researcher.
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
Deepfakes - or fake videos produced to look real through the use of artificial intelligence - pose a growing challenge.
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti
The complexity of molecular structures in the cell is amazing. Having achieved great success in elucidating these structures in recent years, biologists are now taking on the next challenge: to find out more about how they are constructed. A joint research project between two groups from the University of Bern and ETH Zurich now provides insight into a very unusual construction process in the unicellular parasite Trypanosoma brucei.
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1
Solutions for the future of nutritional research
Every day, we choose the food we eat and influence our health, whether consciously or not. This link between diet and health is a core concern of nutritional scientists, who met in Bern from 7 to 12 September 2019 for the 16th annual conference of the NuGO nutrigenomics association.
Every day, we choose the food we eat and influence our health, whether consciously or not. This link between diet and health is a core concern of nutritional scientists, who met in Bern from 7 to 12 September 2019 for the 16th annual conference of the NuGO nutrigenomics association.
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.
Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc
Gabriele Bavota earns an ERC Starting Grant to develop an artificial assistant for software developers
Gabriele Bavota, Assistant Professor at the USI Software Institute (SI), is among the recipients of the latest ERC Starting Grants, the research funds awarded by the European Research Council on a highly competitive basis to the most promising young researchers active in Europe.
Gabriele Bavota, Assistant Professor at the USI Software Institute (SI), is among the recipients of the latest ERC Starting Grants, the research funds awarded by the European Research Council on a highly competitive basis to the most promising young researchers active in Europe.
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of rela
Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of rela
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase
A smart artificial hand for amputees merges user and robotic control
EPFL scientists have successfully tested new neuroprosthetic technology that combines robotic control with users' voluntary control, opening avenues in the new interdisciplinary field of shared control for neuroprosthetic technologies. EPFL scientists are developing new approaches for improved control of robotic hands - in particular for amputees - that combines individual finger control and automation for improved grasping and manipulation.
EPFL scientists have successfully tested new neuroprosthetic technology that combines robotic control with users' voluntary control, opening avenues in the new interdisciplinary field of shared control for neuroprosthetic technologies. EPFL scientists are developing new approaches for improved control of robotic hands - in particular for amputees - that combines individual finger control and automation for improved grasping and manipulation.
Next Monday, the Fall Semester begins for about 27,000 students at the University of Zurich. The number of Master's students in particular has increased.
This weekend in Yverdon, the HydroContest EPFL Team took first place in the nautical competition with its lightweight boat, second place in endurance, and third place in speed with its heavyweight boat.
Approach and landing are among the most complex phases of a flight.
Climate protection thanks to agroforestry
Zurich-Reckenholz, 10.09.2019 - Producing food and feed while protecting the climate - is that possible? Yes, and agroforestry is one option, combining agriculture and wood production on the same land.
Zurich-Reckenholz, 10.09.2019 - Producing food and feed while protecting the climate - is that possible? Yes, and agroforestry is one option, combining agriculture and wood production on the same land.
Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont, Colorado, USA, announced a collaboration to develop and integrate innovative technologies into implantable neuro-devices.
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).
Universities play an increasingly important role in society creating an environment where talents, like graduate student David Yenicelik, thrive.
Novartis data confirm long-term efficacy and safety of Aimovig for majority of patients with episodic migraine
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag
Vontobel Award: Systematic Remembering and Similar Surgical Consequences
This year's Vontobel Award for Research on Age(ing) goes to Burcu Demiray Batur from the University of Zurich, Jonathan Rychen from the University Hospital of Basel and Sarah Stricker from the Hôpital Necker in Paris.
This year's Vontobel Award for Research on Age(ing) goes to Burcu Demiray Batur from the University of Zurich, Jonathan Rychen from the University Hospital of Basel and Sarah Stricker from the Hôpital Necker in Paris.
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
Innovation - 12:01
Swiss- Austrian high- level meeting to share information and perspectives on higher education, research and innovation
Swiss- Austrian high- level meeting to share information and perspectives on higher education, research and innovation
Pharmacology - 07:01
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress